Observational studyIndian journal of pharmacology2026
Impact of probiotic supplementation on chemotherapy and radiotherapy-associated diarrhea and quality of life.
Observational study in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate whether prophylactic oral Lactobacillus supplementation reduces chemotherapy- and radiotherapy-associated diarrhea and helps preserve quality of life (QoL) in adults starting anticancer treatment. MATERIALS AND
methodsThis prospective two-group observational study included adults (18-75 years) receiving their first cycle of chemotherapy and/or radiotherapy at a tertiary cancer center. The Nonprobiotic Group received standard care without probiotics, and the Probiotic Group received standard care plus oral Lactobacillus 60 million colony-forming units twice daily for 6 weeks. Diarrhea was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Use of rescue loperamide, pain on a 10-cm Visual Analog Scale (VAS), and scores on the European Organisation for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC QLQ-C30) were recorded at baseline and at 6 weeks.
resultsOne hundred patients completed follow-up (50 per group). At 6 weeks, Grade ≥ 2 diarrhea occurred in 28% of the Nonprobiotic and 4% of the Probiotic Group. Mean diarrhea score was higher without probiotics (1.26 ± 0.49 vs. 0.78 ± 0.51, P < 0.001), and loperamide use was more frequent (44% vs. 24%, P = 0.034). VAS pain scores decreased significantly over time in both groups. Physical functioning at 6 weeks was slightly better in the probiotic group, while other EORTC QLQ-C30 domains were broadly comparable.
conclusionProphylactic Lactobacillus supplementation was associated with milder treatment-related diarrhoea, reduced rescue loperamide use, and small early gains in physical functioning during chemoradiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.